ResMed Inc. (NYSE:RMD) Shares Bought by Hunter Associates Investment Management LLC

Hunter Associates Investment Management LLC increased its position in ResMed Inc. (NYSE:RMD) by 0.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 50,365 shares of the medical equipment provider’s stock after purchasing an additional 70 shares during the period. ResMed accounts for about 1.9% of Hunter Associates Investment Management LLC’s investment portfolio, making the stock its 10th biggest holding. Hunter Associates Investment Management LLC’s holdings in ResMed were worth $12,292,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. OFI Invest Asset Management bought a new position in ResMed in the second quarter worth about $32,000. BOK Financial Private Wealth Inc. bought a new position in ResMed in the first quarter worth about $35,000. Versant Capital Management Inc lifted its holdings in ResMed by 196.7% in the second quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 120 shares during the last quarter. Financial Connections Group Inc. bought a new position in ResMed in the second quarter worth about $37,000. Finally, Blue Trust Inc. lifted its holdings in ResMed by 182.7% in the second quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 137 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at ResMed

In other ResMed news, insider Justin Leong sold 48,000 shares of ResMed stock in a transaction on Monday, August 5th. The shares were sold at an average price of $217.07, for a total transaction of $10,419,360.00. Following the completion of the sale, the insider now owns 18,741 shares of the company’s stock, valued at $4,068,108.87. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $239.90, for a total transaction of $479,800.00. Following the completion of the transaction, the director now owns 87,204 shares of the company’s stock, valued at $20,920,239.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Justin Leong sold 48,000 shares of the business’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $217.07, for a total transaction of $10,419,360.00. Following the transaction, the insider now owns 18,741 shares in the company, valued at approximately $4,068,108.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 123,874 shares of company stock valued at $28,151,142 in the last quarter. Company insiders own 0.71% of the company’s stock.

ResMed Trading Down 3.6 %

NYSE RMD opened at $246.83 on Tuesday. ResMed Inc. has a twelve month low of $134.12 and a twelve month high of $260.49. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92. The stock has a market cap of $36.23 billion, a price-to-earnings ratio of 32.69, a PEG ratio of 2.05 and a beta of 0.69. The firm’s 50 day moving average price is $241.10 and its two-hundred day moving average price is $218.57.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The firm had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.19 billion. During the same period in the previous year, the company posted $1.64 EPS. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. Equities analysts anticipate that ResMed Inc. will post 9.16 EPS for the current year.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend is Thursday, November 7th. ResMed’s dividend payout ratio (DPR) is currently 28.08%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on RMD. Royal Bank of Canada raised their target price on shares of ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a report on Friday. Baird R W raised ResMed to a “strong-buy” rating in a report on Tuesday, September 24th. Bank of America lifted their price target on ResMed from $240.00 to $270.00 and gave the company a “buy” rating in a report on Thursday, September 26th. KeyCorp lifted their price target on ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a report on Friday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a report on Friday. One research analyst has rated the stock with a sell rating, five have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, ResMed currently has an average rating of “Moderate Buy” and an average price target of $225.70.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.